Practice parameter: Management of dementia (an evidence-based review): Report of the quality standards subcommittee of the American Academy of Neurology

Neurology

Volumn 56, Issue 9, 2001, Pages 1154-1166

  Doody, R S ^a   Stevens, J C ^b   Beck, C ^c   Dubinsky, R M ^d   Kaye, J A ^e   Gwyther, L ^f   Mohs, R C ^g   Thal, L J ^h   Whitehouse, P J ⁱ   DeKosky, S T ^j   Cummings, J L ^k  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Lutheran Medical Office   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; ESTROGEN; NEUROLEPTIC AGENT; SELEGILINE;

AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR MODIFICATION; CAREGIVER; COGNITION; DEMENTIA; DEPRESSION; EVIDENCE BASED MEDICINE; FAMILY COUNSELING; PRIORITY JOURNAL; PSYCHOSIS; REINFORCEMENT; TREATMENT OUTCOME; URINE INCONTINENCE;

EID: 0035826771     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.9.1154     Document Type: Article

References (175)

1. A controlled trial of Tacrine in Alzheimer's disease
2. A 30-week randomized controlled trial of high-dose Tacrine in patients with Alzheimer's disease
3. Hepatotoxic effects of Tacrine administration in patients with Alzheimer's disease
4. Tactine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: A multicentre trial
5. A double-blind, placebo-controlled multicenter study of Tacrine for Alzheimer's disease
6. Tacrine in Alzheimer's disease
7. Tetrahydro-aminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease: Results of a Canadian double-blind, crossover, multicenter study
8. Donepezil improved cognition and global function in Alzheimer's disease
9. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
10. The effects of donepezil in Alzheimer's disease: Results from a multinational trial
11. The efficacy and safety of Donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
12. A randomized trial evaluating the efficacy and safety of ENA 713 rivastigrnine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
13. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of Rivastigmine (Exeloninfinity)
14. Efficacy and safety of Rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
15. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension
16. A 5-month, randomized, placebo-controlled trial of galantamine in AD
17. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease
18. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease
19. Metrifonate treatment of the cognitive deficits of Alzheimer's disease
20. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
21. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer's disease
22. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease
23. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease
24. Clinical trials and therapeutics: Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease
25. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease
26. Two-year treatment of Alzheimer's disease with eptastigmine
27. Failure of long-term high-dose lecithin to retard progression of early-onset Alzheimer's disease
28. A double-blind, placebo controlled trial of high-dose Lecithin in Alzheimer's disease
29. Lu25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease
30. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease
31. Efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer's disease
32. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease
33. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT)
34. Treatment of Alzheimer's disease with a synthetic ACTH 4-9 analog
35. DGAVP (Org 5667) in early Alzheimer's disease patients: An international double-blind, placebo-controlled, multicenter trial
36. Senile dementia of the Alzheimer type treated with Aniracetam: A new nootropic agent
37. The use of the computerized neuropsychological test battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease
38. Long-term and high-dose piracetam treatment of Alzheimer's disease
39. Effects of phosphatidylserine in Alzheimer's disease
40. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type
41. Evaluation of cycloserine in the treatment of Alzheimer's disease
42. A treatment and withdrawal trial of besipirdine in Alzheimer's disease
43. Milacemide: A placebo-controlled study in senile dementia of the Alzheimer type
44. Lack of efficacy of hydergine in patients with Alzheimer's disease
45. A controlled double-blind study of high-dose dihydroergotoxine mesylate (hydergine) in mild dementia
46. Long-term acetyl-L-carnitine treatment in Alzheimer's disease
47. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
48. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type
49. A controlled study of two doses of idebenone in the treatment of Alzheimer's disease
50. Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease
51. L-deprenyl in Alzheimer's disease: Cognitive and behavioral effects
52. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia
53. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
54. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease
55. Clinical trial of indomethacin in Alzheimer's disease
56. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
57. A randomized controlled trial of prednisone in Alzheimer's disease
58. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: A randomized, controlled trial
59. Estrogen for Alzhelmer's disease in women: Randomized, double-blind, placebo-controlled trial
60. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R
61. Placebo-controlled trial of the xanthine derivative propentofylline in dementia
62. Memantine in the treatment of mild to moderate dementia syndrome: A double-blind placebo-controlled study
63. Efficacy and tolerability of memantine in patients with dementia syndrome
64. Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia
65. Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree
66. Oxiracetam in dementia: A double-blind, placebo-controlled study
67. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: A double-blind, placebo-controlled, clinical and EEG/ERP mapping study
68. Nicergline in mild to moderate dementia: A multicenter, double-blind, placebo-controlled study
69. Therapeutic efficacy of vincamine in dementia
70. Naftidrofuryl in the treatment of mild senile dementia: A double-blind study
71. Efficacy of xantinolnicotinate in patients with dementia
72. Fluvoxamine in the treatment of demented elderly patients: A double-blind placebo-controlled study
73. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia
74. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia
75. A double-blind placebo-controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly
76. Early manifestations of dementing illness: Treatment with glycosaminoglycan polysulfate
77. Nimodipine in the treatment of old age dementias
78. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID)
79. Acetyl-L-carnintine in the treatment of mildly demented elderly patients
80. Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: A double-blind, placebo-controlled study
81. Cyclandelate vs. flunarizine: A double-blind study in a selected group of patients with dementia
82. European Pentoxifylline Multi-Infarct Dementia study
83. Pentoxifylline in cerebrovascular dementia
84. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
85. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
86. Olanzepine treatment of psychiatric and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomized, placebo-controlled trials
87. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease
88. Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances
89. Pharmacologic treatment of non-cognitive behavioral disturbances in elderly demented patients
90. Measuring the efficacy of psychopharmacological treatment of psychomotoric restlessness in dementia: Clinical evaluation of tiapride
91. Neuroleptic sensitivity in patients with senile dementia of Lewy body type
92. Zur therapie der multiinfarktdemenz mit Nicergolin 1): Doppelblinde, klinische, psychometrische und EEG-imainguntersuchungen mit 2 dosierungsschemata
93. Desferrioxamine and Alzheimer's disease: Video home behavior assessment of clinical course and measures of brain aluminum
94. Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study
95. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
96. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression
97. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease
98. Moclobemide in elderly patients with cognitive decline and depression
99. Video rating analysis of effect of maprotiline in patients with dementia and depression
100. A double-blind, randomized, fixed-dose trial of fluexetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease
101. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia
102. Decreasing the burden in families caring for a relative with a dementing illness: A controlled study
103. The impact of a support group programme for caregivers on the institutionalisation of demented patients
104. Quasi-experimental evaluation of an educational model for dementia caregivers
105. Education to assist spouses in coping with Alzheimer's disease: A controlled trial
106. The effects of a special computer network on caregivers of persons with Alzheimer's disease
107. Effect of a training programme to reduce stress in carers of patients with dementia
108. A family intervention to delay nursing home placement of patients with Alzheimer disease
109. Reducing antipsychotic drug use in nursing homes
110. The effect of skill training on functional abilities of nursing home residents with dementia
111. Improving eating behaviors in dementia using behavioral strategies
112. Improving dressing behavior in cognitively impaired nursing home residents
113. Behavioral treatment of deficit skills in dementia patients
114. Procedural memory stimulation in Alzheimer's disease: Impact of a training programme
115. 'Rementia': Challenging the limits of dementia care
116. Urinary incontinence associated with dementia
117. Assessment, treatment and management of urinary incontinence in the nursing home
118. Reactivating occupational therapy: A method to improve cognitive performance in geriatric patients
119. Light in the darkness
120. Effects of a multi-strategy program upon elderly with organic brain syndrome
121. Reality orientation and dementia: A controlled trial of two approaches
122. Effects of individualized versus classical "relaxation" music on the frequency of agitation in elderly persons with Alzheimer's disease and related disorders
123. Effects of calming music on the level of agitation in cognitively impaired nursing home residents
124. Influence of dinner music on food intake and symptoms common in dementia
125. Management of verbally disruptive behaviors in nursing home residents
126. Use of music to decrease aggressive behaviors in people with dementia
127. Effects of individualized music on confused and agitated elderly persons
128. The effect of music on repetitive disruptive vocalizations of persons with dementia
129. Effects of music on bathing cooperation for residents with dementia
130. Quiet music: An intervention for mealtime agitation?
131. Evaluation of simulated presence: A personalized approach to enhance well-being in persons with Alzheimer's disease
132. Simulated presence therapy: Using selected memories to manage problem behaviors in Alzheimer's disease patients
133. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia
134. Environmental interventions and functional ability of Alzheimer's disease patients
135. Effects of bright light treatment on agitated behavior in institutionalized elderly subjects
136. Modifying repetitive verbalizations of community-dwelling patients with AD
137. Evaluation of a clinical intervention for wanderers on a geriatric nursing unit
138. A low intensity exercise/movement program for patients with Alzheimer's disease: The TEMP-AD Protocol
139. Single case evaluation of the effects of aromatherapy and massage on disturbed behavior in severe dementia
140. The effectiveness of slow-stroke massage in diffusing agitated behaviors in individuals with Alzheimer's disease
141. Efficacy of hand massage in decreasing agitation behaviors associated with care activities in persons with dementia
142. A randomized trial of dementia care in nursing homes
143. Management of problematic behavioral symptoms associated with dementia: A cognitive developmental approach
144. Effects of an environmental manipulation emphasizing client-centered care on agitation and sleep in dementia sufferers in a nursing home
145. Wellness group: A novel intervention for coping with disruptive behavior in elderly nursing home residents
146. Using a therapy dog to alleviate the agitation and desocialization of people with Alzheimer's disease
147. The effects of a psychomotor activation programme for use in groups of cognitively impaired people in homes for the elderly
148. A dyadic remediation program for care recipients with dementia
149. Effects of language used by caregivers on agitation in residents with dementia
150. Efficacy of a sensory integration program on behaviors of inpatients with dementia
151. Can changes in ward routines affect the severity of dementia? A controlled prospective study
152. Environmental correlates of resident agitation in Alzheimer's disease special care units
153. Catastrophic reactions and other behaviors of Alzheimer's residents: Special unit compared with traditional units
154. Special care units for demented patients: A multicenter study
155. Effectiveness of a continuum of care using brief and partial hospitalization for agitated dementia patients
156. Impact of special care unit for patients with advanced Alzheimer's disease on patients' discomfort and costs
157. The importance of exterior environment for Alzheimer residents: Effective care and risk management
158. The effect of a walled garden on behavior of individuals with Alzheimer's
159. The effects of an enhanced environment on nursing home residents who pace
160. Effects of natural environments upon agitation and aggression in late stage dementia patients
161. Medical outcome of psychosocial intervention in demented patients: One-year clinical follow-up after relocation into group living units
162. Reducing caregiver burden: A randomized psychoeducational intervention for caregivers of persons with dementia
163. A comprehensive support program: Effect of depression in spouse-caregivers of AD patients
164. A nursing intervention to decrease depression in family caregivers of persons with dementia
165. Efficacy of a support group programme for caregivers of demented patients in the community: A randomized controlled trial
166. A randomized trial of family caregiver support in the home management of dementia
167. A controlled study of respite service for caregivers of Alzheimer's patients
168. Effects of respite care on patients with dementia and their caregivers
169. Stress reduction for family caregivers: Effects of adult day care use
170. A study of the characteristics of the dementia patients and caregivers in dementianonspecific adult day care programs
171. Group counseling for relatives of hospitalized presenile dementia patients: A controlled study
172. A model telephone information and support program for caregivers of Alzheimer's patients
173. Assessing the competency of patients with Alzheimer's Disease under different legal standards. A prototype instrument